Bacterial keratitis is a serious and potentially sight-threatening infection of the cornea, the transparent front part of the eye. It is caused by the invasion of bacteria into the corneal tissue, often resulting from corneal trauma, contact lens use, or compromised ocular surfaces. Common bacterial culprits include Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa. Symptoms of bacterial keratitis include eye pain, redness, blurred vision, sensitivity to light, and the sensation of a foreign body in the eye. Timely diagnosis is essential, typically involving a thorough eye examination and corneal cultures. Treatment for bacterial keratitis involves the prompt administration of topical antibiotics specific to the identified bacteria. Severe cases may require additional interventions such as corneal debridement or surgery. Preventive measures include proper contact lens hygiene, avoiding eye trauma, and seeking prompt medical attention for any eye injuries. Prompt and appropriate management is crucial in preventing complications and preserving visual function in cases of bacterial keratitis.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Overcoming biophysical characterization challenges of small antigens in dilute vaccine formulations
Eric Kemp, Merck & Co., United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : A combined LC-MS and immunoassay approach to characterize preservative-induced destabilization of human papillomavirus virus-like particles adsorbed to an aluminum-salt adjuvant
Ria T Caringal, University of Kansas, United States